Autoimmune Diseases, Crohn Disease, Dermatomyositis, Still Disease, Ulcerative Colitis
Conditions
Keywords
CAR T-cell therapy, CD7, Crohn disease, Ulcerative colitis, Dermatomyositis, Still disease, Refractory autoimmune disease
Brief summary
A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells in the Treatment of Autoimmune Diseases
Detailed description
Most patients with autoimmune diseases depend on hormones for life, and when poorly controlled, they are at risk of disability or even death. Studies have found that the abnormal T cell function of patients is closely related to the occurrence and development of the disease. Therefore, reducing the T cells in the patient's body or blocking the function has become the latest breakthrough in treatment. CD7 is a specific antigen on the surface of T cells. CD7 CAR-T can specifically attack T cells and has the potential to cure. In 2019, Science Translational Medicine magazine reported that the Marko Radic team demonstrated that CAR-T cells can achieve significant and long-lasting effects in the treatment of systemic lupus erythematosus (SLE) through animal experiments. In 2021, NEJM magazine reported the clinical efficacy of CAR-T cells in the treatment of SLE. In the same year, Journal of Clinical Oncology reported the clinical efficacy and safety of CD7 CAR-T cells in the treatment of T cell ALL. Based on the current research status, we applied to clinical research on the treatment of refractory autoimmune diseases by targeting CD7 CAR-T cells. The selection criteria is patients with refractory autoimmune diseases. The purpose is to evaluate the safety and effectiveness of targeted CD7 CAR-T cell therapy through this clinical trial study, and to provide clinical evidence and experience reference for the application of CAR-T cell technology in the treatment of refractory autoimmune diseases.
Interventions
BIOLOGICALCD7 CAR T-cells
Each subject receive CD7 CAR T-cells by intravenous infusion
Sponsors
Yake Biotechnology Ltd.
Zhejiang University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Diagnosed as refractory Crohn disease, ulcerative colitis (collectively called Crohn's disease), and the conventional hormone therapy is not effective and (or) there is no effective treatment: 1. At least 6 months before screening, diagnosed as Crohn's disease based on typical radiological results and/or typical histology. 2. In addition to corticosteroids, after the use of immunosuppressive agents (usually azathioprine, methotrexate, and two biological agents (usually infliximab, adalimumab and/or setolizumab), the course of the disease is still Unsatisfactory. Patients should still have relapsed and refractory diseases after glucocorticoid and/or immunosuppressive treatment, or clearly show intolerance/toxicity to these drugs 2. Diagnosed as refractory dermatomyositis, and conventional hormone therapy is not effective and (or) ineffective treatment methods: 1. At least 6 months before screening, confirmed or possible dermatomyositis according to Bohan and Peter criteria; 2. At least it has no response to prednisone and other first-line immunosuppressants (such as methotrexate, mycophenolate mofetil, or azathioprine), or has obvious toxicity or intolerance to these therapies. 3. Refractory adult STILL disease 1. Conform the diagnostic criteria for adult STILL disease (according to Yamaguchi et al., J. Rheumatology, 1992); 2. After receiving non-steroidal anti-inflammatory drugs, glucocorticoids, anti-rheumatic drugs (DMARDs) and other treatments, there are still relapsed and refractory diseases, or clearly show that these drugs are intolerant/toxic. 4. Rheumatoid arthritis 1. Conform the diagnostic criteria for rheumatoid arthritis in 2010 ACR classification criteria; 2. Have received DMARDs or glucocorticoid therapy, but failed to achieve clinical remission, or clearly showed intolerance/toxicity to these drugs. The following screening can be performed by meeting any of the above 4 entry criteria 5. Estimated survival time\> 12 weeks; 6. Patients had a negative urine pregnancy test before the start of administration and agreed to take effective contraceptive measures during the test period until the last follow-up; 7. Patients or their legal guardians volunteer to participate in the study and sign the informed consent.
Exclusion criteria
* Subjects with any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting toxicity (DLT) | Baseline up to 28 days after CD7 targeted CAR T-cells infusion | Adverse events assessed according to NCI-CTCAE v5.0 criteria |
| Incidence of treatment-emergent adverse events (TEAEs) | Up to 2 years after CD7 targeted CAR T-cells infusion | Incidence of treatment-emergent adverse events \[Safety and Tolerability\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of CAR-T cells | From admission to the end of the follow-up, up to 2 years | In peripheral blood and bone marrow |
| Overall response rate (ORR) | At Month 1, 3, 6, 12, 18, 24 | Proportion of subjects with complete or partial remission |
| Overall survival (OS) | From CD7 CAR-T infusion to death，up to 2 years | The time from the cell reinfusion to death due to any cause |
| Duration of remission, DOR | 2 years post CD7 CAR-T cells infusion | The time from the first assessment of remission or partial remission of the disease to the first assessment of disease progression or death from any cause |
| Best overall response, BOR | At ≤3 month | Assessment of ORR at ≤3 month |
Countries
China
Contacts
Primary ContactHe Huang, PhD
Backup ContactYongxian Hu, PhD
Outcome results
None listed